Novartis Breast Cancer Drug Found To Cut Disease Recurrence - Investopedia
Novartis' Kisqali, combined with endocrine therapy, reduced breast cancer recurrence risk by 28.5% beyond the three-year treatment period. The company expects an FDA decision on approval this quarter.
Reference News
Novartis Breast Cancer Drug Found To Cut Disease Recurrence - Investopedia
Novartis' Kisqali, combined with endocrine therapy, reduced breast cancer recurrence risk by 28.5% beyond the three-year treatment period. The company expects an FDA decision on approval this quarter.